DAXI (DaxibotulinumtoxinA) - An Innovative Approach for Frown Lines

• Published in: International journal of general medicine Vol. 16; pp. 1267 - 1269
• Main Authors: Mussarat, Abdullah, Mustafa, Muhammad Saqlain, Azam, Syed Talal, Nafees Uddin, Muhammad Musab, Nasrullah, Rana Muhammad Umer, Siddiq, Mohammad Arham
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01-01-2023; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Aging; botox; Botulinum toxin; Clinical trials; daxibotulinumtoxina; Dermatologic agents; Dermatology; Drug approval; FDA approval; Formulae, receipts, prescriptions; glabellar lines; Muscle function; Patients; Peptides; sakura; Skin; Skin care products; wrinkles; United States > US; wrinkles; glabellar lines; Botox; SAKURA; daxibotulinumtoxinA
• ISSN: 1178-7074; 1178-7074
• DOI: 10.2147/IJGM.S406563

Glabellar frown lines, also known as worry lines, are a common sign of aging. The current treatment option for glabellar lines is subjective and ranges from economical anti-wrinkle creams and skin resurfacing techniques such as microdermabrasion and fillers to highly expensive facelifts. Botox
has been the mainstream treatment for decades, but the suggested time between treatments for most toxins is 12-16 weeks, and evidence shows that patients being treated for glabellar lines want longer-lasting results. Recently, on September 16th, the US Food and Drug Administration (FDA) approved the development of daxibotulinumtoxinA (DAXI) for injection based on clinical trials (SAKURA 1, 2, and 3). These encouraging findings followed by FDA approval mean that the need for repeated treatments to sustain the desired outcome has decreased. DAXI could be a reliable and secure choice for reducing the appearance of wrinkles on the face caused by muscle activity, and its long duration has the potential to enhance the treatment of both therapeutic and cosmetic disorders.